-
Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-03-16 Laure Ponthier, Julie Autmizguine, Benedicte Franck, Anders Åsberg, Philippe Ovetchkine, Alexandre Destere, Pierre Marquet, Marc Labriffe, Jean-Baptiste Woillard
-
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-03-15 Nanja C. Bevers, Ron J. Keizer, Dennis R. Wong, Arta Aliu, Marieke J. Pierik, Luc J. J. Derijks, Patrick F. van Rheenen
-
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-03-14 Teijo I. Saari, John Strang, Ola Dale
-
Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-03-09 Yi Ma, Zaiwei Song, Xinya Li, Dan Jiang, Rongsheng Zhao, Zhanmiao Yi
-
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-03-04
Abstract Background and Objective The combination of niraparib and abiraterone acetate (AA) plus prednisone is under investigation for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Regular-strength (RS) and lower-strength (LS) dual-action tablets (DATs), comprising niraparib 100 mg/AA 500 mg and niraparib
-
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-03-01 Sammy Huygens, Tim Preijers, Francis H. Swaneveld, Ilona Kleine Budde, Corine H. GeurtsvanKessel, Birgit C. P. Koch, Bart J. A. Rijnders
-
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-29 Joseph Piscitelli, Micaela B. Reddy, Lance Wollenberg, Laurence Del Frari, Jason Gong, Linda Wood, Yizhong Zhang, Kyle Matschke, Jason H. Williams
-
Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-28 Dua’a Alrahahleh, Yann Thoma, Ruth Van Daele, Thi Nguyen, Stephanie Halena, Melissa Luig, Sophie Stocker, Hannah Yejin Kim, Jan-Willem Alffenaar
-
A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-24 Alina Sadaf, Min Dong, Amanda Pfeiffer, Teresa Latham, Theodosia Kalfa, Alexander A. Vinks, Russell E. Ware, Charles T. Quinn
-
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-23 Brit S. Rohr, Evelyn Krohmer, Kathrin I. Foerster, Jürgen Burhenne, Martin Schulz, Antje Blank, Gerd Mikus, Walter E. Haefeli
-
Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-15 Yeamin Huh, Jessica Wojciechowski, Vivek S. Purohit
-
Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-15 Marjolein D. van Borselen, Laurens Auke Æmiel Sluijterman, Rick Greupink, Saskia N. de Wildt
-
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-04 Naïm Bouazza, Saïk Urien, Frantz Foissac, Laure Choupeaux, Gabrielle Lui, Léo Froelicher Bournaud, Steeve Rouillon, Yi Zheng, Emmanuelle Bardin, Nathalie Stremler, Katia Bessaci, Tiphaine Bihouee, Emmanuelle Coirier-Duet, Christophe Marguet, Eric Deneuville, Muriel Laurans, Philippe Reix, Michèle Gerardin, Marie Mittaine, Ralph Epaud, Caroline Thumerelle, Laurence Weiss, Romain Berthaud, Michaela Semeraro
-
Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile? Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-02-01 Lina Davies Forsman, Hannah Yejin Kim, Thi Anh Nguyen, Jan-Willem C. Alffenaar
Personalised drug dosing through therapeutic drug monitoring (TDM) is important to maximise efficacy and to minimise toxicity. Hurdles preventing broad implementation of TDM in routine care include the need of sophisticated equipment and highly trained staff, high costs and lack of timely results. Salivary TDM is a non-invasive, patient-friendly alternative to blood sampling, which has the potential
-
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-27 Jonathan Greenzaid, Steven Feldman
-
Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-26 Cindy H. T. Yeung, Julie Autmizguine, Pooja Dalvi, Audrey Denoncourt, Shinya Ito, Pamela Katz, Mehzabin Rahman, Yves Theoret, Andrea N. Edginton
-
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-20
Abstract Background and Objective Recent research indicates a correlation between plasma concentration of P2Y12 inhibitors and clinical events, particularly bleeding, which significantly impeded their clinical therapeutic performance. It is therefore vital to delve into the factors that might affect the plasma concentration. The study aims to summarize population pharmacokinetics/pharmacodynamics (PopPKPD)
-
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-20 Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty
-
Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-18
Abstract Background Cotadutide is a dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonist peptide. The objective of this analysis was to develop a population pharmacokinetic (popPK) model of cotadutide, and to identify any potential effect on the PK from intrinsic and extrinsic covariates. Methods The popPK analysis utilized a non-linear mixed-effects modeling approach using the
-
Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-18 Elijah Weber, Raju Subramanian, William Rowe, Michael Graupe, John Ling, Gong Shen, Rebecca Begley, Jennifer Sager, Scott Wolckenhauer, Martin Rhee, Ramesh Palaparthy, Renu Singh
-
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-10 Yuru Fan, Xuan Zhang, Qin Zhang, Liang Zheng, Renpeng Zhou, Cheng Sun, Xihan Wang, Ke Song, Zhusheng He, Honghui Wang, Qian Zhang, Wei Hu
-
Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-06 Dan Shi, Lin Chen, Gexuan Li, Nan Wu, Fengyi Zhang, Xiaofei Wang, Nan Mu, Xi Chen, Xiangyi Yang, Jia Lu, Yali Lu, Meixia Wang, Dongliang Zhang
-
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-05 K. P. van Rhee, C. A. J. Knibbe, P. D. van der Linden, R. J. M. Brüggemann
-
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-04 Jacqueline Gerhart, Donna S. Cox, Ravi Shankar P. Singh, Phylinda L. S. Chan, Rohit Rao, Richard Allen, Haihong Shi, Joanna C. Masters, Bharat Damle
-
Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass Clin. Pharmacokinet. (IF 4.5) Pub Date : 2024-01-02 Audrick Gibert, Julien Lanoiselée, Isabelle Gouin-Thibault, Adeline Pontis, Kasra Azarnoush, Andranik Petrosyan, Nathalie Grand, Serge Molliex, Jérome Morel, Laurent Gergelé, Sophie Hodin, Valérie Bin, Robin Chaux, Xavier Delavenne, Edouard Ollier
-
Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-12-23 Maddalena Centanni, Mirjam E. van de Velde, Aniek Uittenboogaard, Gertjan J. L. Kaspers, Mats O. Karlsson, Lena E. Friberg
-
Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-12-21 Jessica Le Blanc, Denis Projean, Sandra Savignac, Sophie Léveillé, Marie-Pier Ducas, Annie Brisebois-Boyer, Amélie Marsot
-
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-12-11 Joseph Chen, Alessandra Bearz, Dong-Wan Kim, Hirva Mamdani, Jessica Bauman, Rita Chiari, Sai-Hong Ignatius Ou, Benjamin J. Solomon, Ross A. Soo, Enriqueta Felip, Alice T. Shaw, Holger Thurm, Jill S. Clancy, Kimberly Lee, Melissa O’Gorman, Cherie Tanski, Yazdi K. Pithavala
-
Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-26 Iris K. Minichmayr, Sebastian G. Wicha, Peter Matzneller, Charlotte Kloft, Markus Zeitlinger
-
Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-22 Kine Eide Kvitne, Markus Hovd, Line Kristin Johnson, Christine Wegler, Cecilia Karlsson, Per Artursson, Shalini Andersson, Rune Sandbu, Jøran Hjelmesæth, Eva Skovlund, Rasmus Jansson-Löfmark, Hege Christensen, Anders Åsberg, Ida Robertsen
-
Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-20 Ling Song, Fangrui Cao, Shu Niu, Michael Xu, Ruifang Liang, Ke Ding, Zhigang Lin, Xueting Yao, Dongyang Liu
-
How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400–600 mg·h/L-Targeted Dosing Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-16 Tan Zhang, Elke H. J. Krekels, Cornelis Smit, Eric P. A. van Dongen, Roger J. M. Brüggemann, Catherijne A. J. Knibbe
-
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-16 Theresa Pecho, Markus Zeitlinger
-
Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-13 Ahmed Nader, Elizabeth Alexander, Dimitra Brintziki, Amina Z. Haggag, Stephen A. Harrison, Ian A. Hawes, Marjan Hezareh, Andrew M. Lippa, Arisa Okamasa, Malek Okour, Nobuhiko Okuda, Jennifer E. Sager, Scott Segal, Yuri Shida, Andrew Skingsley, Robert Williams, Esther Y. Yoon, Daren Austin
-
Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-14 Xiaomei I. Liu, Dionna J. Green, John van den Anker, Homa K. Ahmadzia, Gilbert J. Burckart, André Dallmann
-
Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-03 Katsumi Iga, Akiko Kiriyama
-
Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-11-02 Jessica Wojciechowski, Vivek S Purohit, Yeamin Huh, Christopher Banfield, Timothy Nicholas
-
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-26 Hironobu Tsukada, Yu-Luan Chen, Guangqing Xiao, Lisa Lennek, Snezana M. Milanovic, MaryAlice Worden, Daniel G. Polhamus, Yu-Yuan Chiu, Seth C. Hopkins, Gerald R. Galluppi
-
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-24 Roland Heinig, Thomas Eissing
-
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-19 Leila S. Otten, Berber Piet, Demy van den Haak, Robert D. Schouten, Milou Schuurbiers, Sushil K. Badrising, Emmy Boerrigter, Sjaak A. Burgers, Rob ter Heine, Michel M. van den Heuvel
-
Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-14 Yuan Li, Ying Zheng, Bing Xu, Linrui Cai, Sheng Feng, Yiming Liu, Zhenyi Zhu, Qin Yu, Hongyan Guo
-
Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-12 Claire Grange, Catherine Rioufol, Pierre-Jean Souquet, Souad Assaad
-
Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-10 Angel Luis Salcedo-Mingoarranz, Susanna Edith Medellín-Garibay, Emilia Barcia-Hernández, Benito García-Díaz
-
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-11 Anouk M. E. Jansen, Beatrijs Mertens, Isabel Spriet, Paul E. Verweij, Jeroen Schouten, Joost Wauters, Yves Debaveye, Rob ter Heine, Roger J. M. Brüggemann
-
High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-11 Anouk M. E. Jansen, Rob ter Heine, Paul E. Verweij, Roger J. M. Brüggemann
-
Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs) Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-12 Sebastian Sten, Tim Cardilin, Madeleine Antonsson, Peter Gennemark
-
Bridging the Worlds of Pharmacometrics and Machine Learning Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-06 Kamilė Stankevičiūtė, Jean-Baptiste Woillard, Richard W. Peck, Pierre Marquet, Mihaela van der Schaar
-
Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-10-06 Anne-Kristina Mercier, Mikael Sunnåker, Sebastian Ueckert, Tadeusz Pawlik, Emilia Henricson, Oleksandr Molodetskyi, Gordon C. Law, Victoria E. R. Parker, Jan Oscarsson
-
Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-30 Terra M. Kruger, Belén Valenzuela, Charles D. Thompson, Sivi Ouwerkerk-Mahadevan, Juan Jose Perez Ruixo
-
Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-27 Ethan A. Poweleit, Zachary L. Taylor, Tomoyuki Mizuno, Samuel E. Vaughn, Zeruesenay Desta, Jeffrey R. Strawn, Laura B. Ramsey
-
Authors' Reply to Ganijee et al.: "Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults". Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-26 Michael Boettcher,Corina Becker
-
Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-20 Michael Murray
The treatment of patients infected with the hepatitis C virus (HCV) has been revolutionised by the development of direct-acting antiviral agents (DAAs) that target specific HCV proteins involved in viral replication. The first DAAs were associated with clinical problems such as adverse drug reactions and pharmacokinetic drug–drug interactions (DDIs). Current FDA/EMA-approved treatments are combinations
-
Cannabidiol Exposure Through Maternal Marijuana Use: Predictions in Breastfed Infants Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-21 Cindy H. T. Yeung, Kerri A. Bertrand, Brookie M. Best, Edmund Capparelli, Christina D. Chambers, Dagmar M. Hajducek, Abdullah Hamadeh, Shinya Ito, Jeremiah D. Momper, Andrea N. Edginton
-
Multivariate Exact Discrepancy: A New Tool for PK/PD Model Evaluation Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-17 Sarah Baklouti, Emmanuelle Comets, Peggy Gandia, Didier Concordet
-
Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-15 Li Ding, Shang Liu, Hao Yan, Zhenyuan Li, Yijun Zhou, Huihua Pang, Renhua Lu, Weiming Zhang, Miaolin Che, Lin Wang, Qin Wang, Wei Fang, Minfang Zhang, Xiajing Che, Leyi Gu
-
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1 Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-16 Mirjam de With, Leni van Doorn, Esmay Kloet, Anne van Veggel, Maja Matic, Micha J. de Neijs, Esther Oomen - de Hoop, Esther van Meerten, Ron H. N. van Schaik, Ron H. J. Mathijssen, Sander Bins
-
Imeglimin: A Clinical Pharmacology Review Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-15 Clémence Chevalier, Pascale Fouqueray, Sébastien Bolze
-
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-09-06 Hauke Ruehs, Alexander Solms, Matthias Frei, Corina Becker, Maria E. Trujillo, Dirk Garmann, Michaela Meyer
-
Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-08-30 Jason E. Lang, Rodrigo Gonzalez Ramirez, Stephen Balevic, Scott Bickel, Christoph P. Hornik, J. Marc Majure, Saranya Venkatachalam, Jessica Snowden, Brian O’Sullivan, Laura James
-
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation Clin. Pharmacokinet. (IF 4.5) Pub Date : 2023-08-28 Prajakta Badri, Bahru Habtemariam, Megan Melch, Valerie A. Clausen, Seth Arum, Xingyu Li, Patrick Y. Jay, John Vest, Gabriel J. Robbie